74D Stock Overview
A specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular markets in Canada, the United States, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
HLS Therapeutics Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$2.20 |
| 52 Week High | CA$3.42 |
| 52 Week Low | CA$1.95 |
| Beta | 1.07 |
| 11 Month Change | -12.00% |
| 3 Month Change | 11.11% |
| 1 Year Change | -5.17% |
| 33 Year Change | -80.00% |
| 5 Year Change | n/a |
| Change since IPO | -79.46% |
Recent News & Updates
Recent updates
Shareholder Returns
| 74D | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 5.8% | -1.0% | 0.2% |
| 1Y | -5.2% | -19.3% | 8.5% |
Return vs Industry: 74D exceeded the German Pharmaceuticals industry which returned -19.3% over the past year.
Return vs Market: 74D underperformed the German Market which returned 8.5% over the past year.
Price Volatility
| 74D volatility | |
|---|---|
| 74D Average Weekly Movement | 8.2% |
| Pharmaceuticals Industry Average Movement | 6.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.3% |
Stable Share Price: 74D's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 74D's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 91 | Craig Millian | www.hlstherapeutics.com |
HLS Therapeutics Inc., a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular markets in Canada, the United States, and internationally. The company’s product portfolio includes Clozaril, an atypical antipsychotic for management of symptoms of treatment-resistant schizophrenia; and Vascepa, an icosapent ethyl capsules for cardiovascular disease. It also distributes MyCare psychiatry lab assays; and MyCare Insite, a point-of-care device to measure patient drug levels.
HLS Therapeutics Inc. Fundamentals Summary
| 74D fundamental statistics | |
|---|---|
| Market cap | €74.70m |
| Earnings (TTM) | -€21.16m |
| Revenue (TTM) | €54.68m |
1.4x
P/S Ratio-3.5x
P/E RatioIs 74D overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 74D income statement (TTM) | |
|---|---|
| Revenue | US$56.94m |
| Cost of Revenue | US$14.36m |
| Gross Profit | US$42.59m |
| Other Expenses | US$64.62m |
| Earnings | -US$22.03m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.69 |
| Gross Margin | 74.79% |
| Net Profit Margin | -38.70% |
| Debt/Equity Ratio | 85.4% |
How did 74D perform over the long term?
See historical performance and comparison